Immunological activation following transcutaneous delivery of HR-gp100 protein

Shoshana Frankenburg; Igor Grinberg; Ziva Bazak; Lena Fingerut; Jacob Pitcovski; Raphael Gorodetsky; Tamar Peretz; Ram M. Spira; Yehuda Skornik; Ronald S. Goldstein

doi:10.1016/j.vaccine.2007.04.025

Immunological activation following transcutaneous delivery of HR-gp100 protein

Shoshana Frankenburg
, Igor Grinberg
, Ziva Bazak
, Lena Fingerut
, Jacob Pitcovski
, Raphael Gorodetsky
, Tamar Peretz
, Ram M. Spira
, Yehuda Skornik
, Ronald S. Goldstein

The Mina and Everard Goodman Faculty of Life Sciences - at Bar-Ilan University

Hadassah University Medical Centre
Migal Galilee Technology Center Israel
Shaare Zedek Medical Center
Tel Aviv Sourasky Medical Center

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

Transcutaneous immunization aims at taking advantage of the skin's immune system for the purpose of immunoprotection. In the present study, we evaluated the potential of topical delivery of a recombinant melanoma protein, HR-gp100, derived from a shortened sequence of the native gp100 gene. The protein was applied on the skin, with and without the addition of two forms of heat labile enterotoxin (nLT and LTB). HR-gp100 fused to Haptide, a cell penetrating 20mer peptide (HR-gp100H) was also tested. Topical HR-gp100 and HR-gp100H application on the ears of mice elicited the production of specific antibodies, and transcutaneous delivery to intact human skin induced dose-dependent LC activation. nLT and LTB also activated LC, but did not further increase the activation induced by HR-gp100. These results show that HR-gp100, an antigenic tumor-derived protein, activates the immune system following transcutaneous delivery, as shown by both Langerhans cell activation and induction of antibody production.

Original language	English
Pages (from-to)	4564-4570
Number of pages	7
Journal	Vaccine
Volume	25
Issue number	23
DOIs	https://doi.org/10.1016/j.vaccine.2007.04.025
State	Published - 6 Jun 2007

Bibliographical note

Funding Information:
This work was supported by the Chief Scientist of the Israel Ministry of Industry and Commerce, and by NIH grant 1 R21 CA114160-01A1 (to S.F.). We wish to thank Dr. Gerard Marx from Hapto Biotech for his help and advice.

Funding

This work was supported by the Chief Scientist of the Israel Ministry of Industry and Commerce, and by NIH grant 1 R21 CA114160-01A1 (to S.F.). We wish to thank Dr. Gerard Marx from Hapto Biotech for his help and advice.

Funders	Funder number
Chief Scientist of the Israel Ministry of Industry and Commerce
National Institutes of Health
National Cancer Institute	R21CA114160

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Langerhans cells
Melanoma
Transcutaneous vaccination

Access to Document

10.1016/j.vaccine.2007.04.025

Cite this

@article{189d8dd510d447308a588cd2834961e7,

title = "Immunological activation following transcutaneous delivery of HR-gp100 protein",

abstract = "Transcutaneous immunization aims at taking advantage of the skin's immune system for the purpose of immunoprotection. In the present study, we evaluated the potential of topical delivery of a recombinant melanoma protein, HR-gp100, derived from a shortened sequence of the native gp100 gene. The protein was applied on the skin, with and without the addition of two forms of heat labile enterotoxin (nLT and LTB). HR-gp100 fused to Haptide, a cell penetrating 20mer peptide (HR-gp100H) was also tested. Topical HR-gp100 and HR-gp100H application on the ears of mice elicited the production of specific antibodies, and transcutaneous delivery to intact human skin induced dose-dependent LC activation. nLT and LTB also activated LC, but did not further increase the activation induced by HR-gp100. These results show that HR-gp100, an antigenic tumor-derived protein, activates the immune system following transcutaneous delivery, as shown by both Langerhans cell activation and induction of antibody production.",

keywords = "Langerhans cells, Melanoma, Transcutaneous vaccination",

author = "Shoshana Frankenburg and Igor Grinberg and Ziva Bazak and Lena Fingerut and Jacob Pitcovski and Raphael Gorodetsky and Tamar Peretz and Spira, \{Ram M.\} and Yehuda Skornik and Goldstein, \{Ronald S.\}",

note = "Funding Information: This work was supported by the Chief Scientist of the Israel Ministry of Industry and Commerce, and by NIH grant 1 R21 CA114160-01A1 (to S.F.). We wish to thank Dr. Gerard Marx from Hapto Biotech for his help and advice.",

year = "2007",

month = jun,

day = "6",

doi = "10.1016/j.vaccine.2007.04.025",

language = "אנגלית",

volume = "25",

pages = "4564--4570",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd.",

number = "23",

}

TY - JOUR

T1 - Immunological activation following transcutaneous delivery of HR-gp100 protein

AU - Frankenburg, Shoshana

AU - Grinberg, Igor

AU - Bazak, Ziva

AU - Fingerut, Lena

AU - Pitcovski, Jacob

AU - Gorodetsky, Raphael

AU - Peretz, Tamar

AU - Spira, Ram M.

AU - Skornik, Yehuda

AU - Goldstein, Ronald S.

N1 - Funding Information: This work was supported by the Chief Scientist of the Israel Ministry of Industry and Commerce, and by NIH grant 1 R21 CA114160-01A1 (to S.F.). We wish to thank Dr. Gerard Marx from Hapto Biotech for his help and advice.

PY - 2007/6/6

Y1 - 2007/6/6

N2 - Transcutaneous immunization aims at taking advantage of the skin's immune system for the purpose of immunoprotection. In the present study, we evaluated the potential of topical delivery of a recombinant melanoma protein, HR-gp100, derived from a shortened sequence of the native gp100 gene. The protein was applied on the skin, with and without the addition of two forms of heat labile enterotoxin (nLT and LTB). HR-gp100 fused to Haptide, a cell penetrating 20mer peptide (HR-gp100H) was also tested. Topical HR-gp100 and HR-gp100H application on the ears of mice elicited the production of specific antibodies, and transcutaneous delivery to intact human skin induced dose-dependent LC activation. nLT and LTB also activated LC, but did not further increase the activation induced by HR-gp100. These results show that HR-gp100, an antigenic tumor-derived protein, activates the immune system following transcutaneous delivery, as shown by both Langerhans cell activation and induction of antibody production.

AB - Transcutaneous immunization aims at taking advantage of the skin's immune system for the purpose of immunoprotection. In the present study, we evaluated the potential of topical delivery of a recombinant melanoma protein, HR-gp100, derived from a shortened sequence of the native gp100 gene. The protein was applied on the skin, with and without the addition of two forms of heat labile enterotoxin (nLT and LTB). HR-gp100 fused to Haptide, a cell penetrating 20mer peptide (HR-gp100H) was also tested. Topical HR-gp100 and HR-gp100H application on the ears of mice elicited the production of specific antibodies, and transcutaneous delivery to intact human skin induced dose-dependent LC activation. nLT and LTB also activated LC, but did not further increase the activation induced by HR-gp100. These results show that HR-gp100, an antigenic tumor-derived protein, activates the immune system following transcutaneous delivery, as shown by both Langerhans cell activation and induction of antibody production.

KW - Langerhans cells

KW - Melanoma

KW - Transcutaneous vaccination

UR - https://www.scopus.com/pages/publications/34248334248

U2 - 10.1016/j.vaccine.2007.04.025

DO - 10.1016/j.vaccine.2007.04.025

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 17493711

AN - SCOPUS:34248334248

SN - 0264-410X

VL - 25

SP - 4564

EP - 4570

JO - Vaccine

JF - Vaccine

IS - 23

ER -

Immunological activation following transcutaneous delivery of HR-gp100 protein

Abstract

Bibliographical note

Funding

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this